Eleusis Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 39

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $29M

Eleusis General Information

Description

Developer of psychedelic drug therapies intended to address unmet needs within and beyond psychiatry. The company's pipeline features a novel approach to transform psilocybin into a safe, effective, convenient, and affordable treatment alternative for depression, enabling healthcare providers and pharmaceutical companies to address a broad range of needs that are unmet by conventional therapies.

Contact Information

Website
www.eleusisltd.com
Formerly Known As
Eleusis Interim Holdings
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 25 Farringdon Street
  • 6th Floor
  • London EC4A 4AB
  • England, United Kingdom
Primary Industry
Drug Discovery
Acquirer
Beckley Psytech
Vertical(s)
Life Sciences
Corporate Office
  • 25 Farringdon Street
  • 6th Floor
  • London EC4A 4AB
  • England, United Kingdom

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Eleusis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 20-Oct-2022 $29M Completed Generating Revenue
6. Reverse Merger 20-Jan-2022 Cancelled Clinical Trials - General
5. Later Stage VC 08-Jul-2020 Cancelled Clinical Trials - General
4. Later Stage VC (Series A) 01-Jan-2020 Completed Clinical Trials - General
3. Seed Round 27-Jun-2016 Completed Clinical Trials - General
2. Grant 01-Jul-2014 $16.1K $3.5M Completed Startup
1. Seed Round $3.5M $3.5M Completed Startup
To view Eleusis’s complete valuation and funding history, request access »

Eleusis Patents

  • 8

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • Pending

  • Expiring in next 12 mo

Eleusis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230277568-A1 Method of treatment for psilocybin or psilocin infusion Inactive 10-Jul-2020
WO-2019079742-A1 Methods and systems for enhancing safety of psychedelic drug therapies Inactive 19-Oct-2017
WO-2019079742-A8 Methods and systems for enhancing safety of psychedelic drug therapies Inactive 19-Oct-2017
US-20200147038-A1 Assessing and treating psychedelic-responsive subjects Inactive 20-Apr-2017
WO-2018195455-A1 Assessing and treating psychedelic-responsive subjects Inactive 20-Apr-2017 A61K31/48
To view Eleusis’s complete patent history, request access »

Eleusis Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Eleusis Former Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Ambria Capital Venture Capital Minority
Neo Kuma Ventures Venture Capital Minority
Noetic Fund Venture Capital Minority
Palo Santo Venture Capital Minority
Receptor Partners Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

Eleusis Acquisitions (1)

Eleusis’s most recent deal was a Merger/Acquisition with Kalypso Wellness Centers. The deal was made on 15-Jan-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Kalypso Wellness Centers 15-Jan-2021 Merger/Acquisition Clinics/Outpatient Services
To view Eleusis’s complete acquisitions history, request access »

Ready to get started?

Request a free trial

Eleusis FAQs

  • When was Eleusis founded?

    Eleusis was founded in 2013.

  • Where is Eleusis headquartered?

    Eleusis is headquartered in London, United Kingdom.

  • What is the size of Eleusis?

    Eleusis has 39 total employees.

  • What industry is Eleusis in?

    Eleusis’s primary industry is Drug Discovery.

  • Is Eleusis a private or public company?

    Eleusis is a Private company.

  • What is the current valuation of Eleusis?

    The current valuation of Eleusis is .

  • What is Eleusis’s current revenue?

    The current revenue for Eleusis is .

  • How much funding has Eleusis raised over time?

    Eleusis has raised $14.5M.

  • Who are Eleusis’s investors?

    Ambria Capital, Neo Kuma Ventures, Noetic Fund, Palo Santo, and Receptor Partners are 5 of 7 investors who have invested in Eleusis.

  • When was Eleusis acquired?

    Eleusis was acquired on 20-Oct-2022.

  • Who acquired Eleusis?

    Eleusis was acquired by Beckley Psytech.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process